Company news from the 04/28/06 News Brief

Share this article:
Cytogen Corporation and Savient Pharmaceuticals reached a distribution agreement granting Cytogen exclusive marketing rights for Soltamox (tamoxifen citrate) in the US. Financial terms of the agreement were not disclosed. Soltamox, a cytostatic estrogen receptor antagonist, is the first oral liquid hormonal therapy approved in the US. It is indicated for the treatment of breast cancer in adjuvant and metastatic settings and to reduce the risk of breast cancer in women with ductal carcinoma in situ (DCIS) or with high risk of breast cancer.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.